Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement

• Status: Recruiting
• Trial end date: 2022-06-15
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aim to compare subacromial ketorolac (non-steroidal anti-inflammatory drug) versus methylprednisolone (steroid) for the treatment of shoulder impingement syndrome.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Medical Branch, Galveston
• Treatments: Ketorolac; Ketorolac Tromethamine; Lidocaine; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Age >18 years

• Severe or recalcitrant shoulder impingement syndrome

• Subacromial injection is a therapeutic option

Exclusion Criteria:

• Allergy or intolerance to steroids within less than 1 month

• Allergy or intolerance to NSAIDs within less than 1 month

• Pregnancy

• Breastfeeding

• Pre-existing asthma

• Uncontrolled psychiatric illness

• Previous shoulder injection within the past 3 months

• Evidence of confounding shoulder pathology on imaging

• History of a full-thickness rotator cuff tear

• Ipsilateral cervical radiculopathy

• Moderate to severe glenohumeral arthritis

• Systemic inflammatory conditions

• Kidney disease

• Liver disease

• Gastrointestinal ulcer

• Bleeding disorder

• Pending litigation or work-related claims related to the shoulder

• Previous shoulder surgery on the affected shoulder

• Evidence of local infection

• Evidence of adhesive capsulitis

• Evidence of shoulder instability